Differentially-regulated prostate cancer genes
OwnerZairen Sun, Gilbert Jayinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides are differentially-regulated in prostate cancer and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, to prostate cancer.
Claims21
A method of determining the presence of prostate cancer cells in a sample comprising nucleic acid, comprising:
- contacting said sample with a polynucleotide probe under conditions effective for said probe to hybridize specifically to a target nucleic acid in said sample,
- detecting the amount of hybridization between said probe and target nucleic acid, and
- determining by said hybridization whether said target nucleic acid is differentially-regulated in said sample, whereby the presence of a differentially-regulated target nucleic acid indicates that said sample comprises cancer cells,
- wherein said probe comprises a polynucleotide sequence which is selected from Table 1 or 2, a polynucleotide having 95% sequence identity or more to a polynucleotide sequence selected from Table 1 or 2, effective specific fragments thereof, or complements thereto.
A method for diagnosing a prostate cancer in a sample comprising prostate tissue, comprising:
- determining the number of target genes which are differentially-regulated in said sample, wherein said target genes are selected from Table 1 or 2, or, a gene represented by a sequence having 95% sequence identity or more to a sequence selected from Table 1 or 2,
- wherein said genes are differentially-regulated in prostate cancer, and
- whereby said number is indicative of the probability that said sample comprises prostate cancer.
A method of clam 5, wherein said probe is a contiguous sequence of at least 16 nucleotides selected from a polynucleotide listed in Table 1 or 2, or a complement thereto.
A method of assessing a therapeutic or preventative intervention in a subject having a prostate cancer, comprising,
- detecting the expression levels of differentially-regulated genes, wherein the target genes comprise a gene which is represented by a polynucleotide listed in Table 1 or 2 of claim 21, or, a gene represented by a sequence having 95% sequence identity thereto.
A method for identifying agents that modulate the expression of target polynucleotides differentially-regulated in prostate cancer cells, comprising,
- contacting a prostate cell population with a test agent under conditions effective for said test agent to modulate the expression of a target polynucleotide in said cell population, and
- determining whether said test agent modulates said target polynucleotide expression, wherein said target polynucleotide is selected from Table 1 or 2 of claim 21, a polynucleotide having 95% sequence identity thereto, effective specific fragments thereof, or complements thereto, and said polynucleotide is differentially-regulated in a prostate cancer.
A method for identifying agents that modulate a biological activity of a polypeptide differentially-regulated in prostate cancer cells, comprising,
- contacting a polypeptide differentially-regulated in prostate cancer cells with a test agent under conditions effective for said test agent to modulate a biological activity of said polypeptide, and
- determining whether said test agent modulates said biological activity, wherein said polypeptide is coded for by a polynucleotide listed in Table 1 or 2, of claim 21, a polynucleotide having 95% sequence identity thereto, effective specific fragments thereof, or complements thereto, and said polynucleotide is differentially-regulated in a prostate cancer.
A method of treating prostate cancer, comprising,
- administering to a subject in need thereof a therapeutic agent which is effective for regulating expression of at least one gene selected from Table 1 or 2 of claim 21, wherein said gene is differentially-regulated in said cancer.
A method of diagnosing a prostate cancer comprising:
- assessing the expression of at least one gene selected from Table 1 or 2 of claim 21, wherein said gene is differentially-regulated in said cancer.
A method of retrieving prostate cancer differentially-regulated gene sequences from a computer-readable medium, comprising:
- selecting a gene expression profile that specifies that said gene is differentially-regulated in a prostate cancer, and retrieving prostate cancer differentially-regulated gene sequences,
- where the gene sequences consist of the sequences of polynucleotides listed in Tables 1 or 2 of claim 21, a polynucleotide having 95% sequence identity thereto, effective specific fragments thereof, or complements thereto.
An ordered array of polynucleotide probes for detecting the expression of differentially-regulated prostate cancer genes in a sample, comprising:
- polynucleotide probes associated with a solid support, wherein each probe is specific for a different differentially-regulated prostate cancer gene, and the probes comprise a nucleotide sequence selected the polynucleotides listed in from Table 1 or 2 of claim 21, or a complement thereto.
A computer-readable storage medium, consisting essentially of, one or more differentially-regulated cancer prostate genes which are selected from Table 1 or 2, a polynucleotide having 95% sequence identity thereto, effective specific fragments thereof, or complements thereto, and said polynucleotide is differentially-regulated in said prostate cancer.
Dependencies are inferred from the claim text.